CRM vs PFE: Which Is the Better Buy?
Side-by-side comparison of Salesforce, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-22.
Salesforce, Inc. · Technology
$236.42
+11.6% upside to fair value
Med Conviction
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRM |
PFE |
| Current Price |
$236.42 |
$27.64 |
| Fair Value Estimate |
$263.88 |
$30.94 |
| Upside to Fair Value |
+11.6%
|
+12.0%
|
| Market Cap |
$193.6B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
14.4x
|
17.4x
|
| Price / Sales |
4.4x
|
2.5x
|
| Price / FCF |
12.8x
|
14.3x
|
| Revenue Growth YoY |
+10.8%
|
+2.6%
|
| Gross Margin |
77.3%
|
71.3%
|
| Operating Margin |
21.4%
|
25.1%
|
| Return on Equity |
20.2%
|
4.9%
|
| Dividend Yield |
0.73% |
6.22% |
| FCF Yield |
7.82%
|
6.97%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Salesforce is the leading enterprise customer relationship management platform, spanning Sales, Service, Platform, Marketing, Commerce, Tableau, MuleSoft, and Slack under the Customer 360 umbrella, with 83,334 employees and a business that converts $53.65 of revenue per share into $18.48 of free cash flow per share. Business quality is high: TTM gross margin of 77.3%, TTM operating margin of 21.4…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
CRM |
PFE |
| Zone Low |
$197.91 |
$23.21 |
| Zone High |
$224.30 |
$26.30 |
| In Buy Zone? |
No
|
No
|